ADAR1 Capital Management LLC Acquires 18,509 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

ADAR1 Capital Management LLC grew its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) by 142.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 31,509 shares of the company’s stock after purchasing an additional 18,509 shares during the quarter. ADAR1 Capital Management LLC owned about 0.06% of Janux Therapeutics worth $1,687,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in JANX. Russell Investments Group Ltd. lifted its position in Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock worth $54,000 after buying an additional 442 shares in the last quarter. Avanza Fonder AB bought a new position in shares of Janux Therapeutics in the fourth quarter worth about $139,000. Meeder Asset Management Inc. bought a new stake in shares of Janux Therapeutics during the fourth quarter valued at approximately $159,000. Chicago Capital LLC bought a new stake in shares of Janux Therapeutics during the fourth quarter valued at approximately $230,000. Finally, Cerity Partners LLC acquired a new stake in shares of Janux Therapeutics in the fourth quarter valued at approximately $239,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Down 4.5 %

NASDAQ:JANX opened at $25.77 on Monday. Janux Therapeutics, Inc. has a twelve month low of $24.30 and a twelve month high of $71.71. The company has a market cap of $1.52 billion, a P/E ratio of -22.03 and a beta of 3.27. The business has a 50 day moving average price of $34.09 and a two-hundred day moving average price of $45.24.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on JANX shares. Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. Scotiabank lowered their price target on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research note on Friday, February 28th. HC Wainwright reiterated a “buy” rating and issued a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $200.00 price objective on shares of Janux Therapeutics in a report on Wednesday, December 11th. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $92.44.

Insider Activity at Janux Therapeutics

In related news, Director Ra Capital Management, L.P. purchased 110,206 shares of the stock in a transaction on Friday, March 7th. The shares were purchased at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the acquisition, the director now directly owns 10,141,287 shares in the company, valued at $314,582,722.74. The trade was a 1.10 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO David Alan Campbell sold 5,000 shares of Janux Therapeutics stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief executive officer now owns 293,054 shares of the company’s stock, valued at approximately $17,583,240. The trade was a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,668 shares of company stock valued at $548,183. 29.40% of the stock is owned by insiders.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.